MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Short Interest Down 13.9% in February

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) saw a large decrease in short interest in the month of February. As of February 27th, there was short interest totaling 489,206 shares, a decrease of 13.9% from the February 12th total of 568,283 shares. Based on an average daily volume of 98,615 shares, the short-interest ratio is presently 5.0 days. Currently, 1.3% of the company’s shares are sold short. Currently, 1.3% of the company’s shares are sold short. Based on an average daily volume of 98,615 shares, the short-interest ratio is presently 5.0 days.

MIRA Pharmaceuticals Trading Down 3.8%

Shares of NASDAQ:MIRA traded down $0.05 during mid-day trading on Wednesday, reaching $1.13. The stock had a trading volume of 133,491 shares, compared to its average volume of 141,080. The firm has a 50 day simple moving average of $1.28 and a two-hundred day simple moving average of $1.39. MIRA Pharmaceuticals has a twelve month low of $0.73 and a twelve month high of $2.45. The firm has a market cap of $47.11 million, a PE ratio of -0.74 and a beta of 1.78.

Institutional Investors Weigh In On MIRA Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. First American Bank grew its holdings in shares of MIRA Pharmaceuticals by 20.0% in the 4th quarter. First American Bank now owns 60,000 shares of the company’s stock valued at $91,000 after buying an additional 10,000 shares during the period. Fifth Third Bancorp bought a new stake in shares of MIRA Pharmaceuticals in the 4th quarter valued at $30,000. XTX Topco Ltd acquired a new stake in MIRA Pharmaceuticals during the 2nd quarter worth $26,000. Creative Planning acquired a new stake in MIRA Pharmaceuticals during the 2nd quarter worth $27,000. Finally, Two Sigma Investments LP lifted its holdings in MIRA Pharmaceuticals by 129.8% during the third quarter. Two Sigma Investments LP now owns 45,703 shares of the company’s stock worth $62,000 after acquiring an additional 25,816 shares in the last quarter. 35.16% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

MIRA has been the subject of several analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of MIRA Pharmaceuticals in a research report on Monday, December 29th. Wall Street Zen lowered shares of MIRA Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, November 22nd. Finally, Rodman & Renshaw began coverage on shares of MIRA Pharmaceuticals in a research note on Tuesday, January 13th. They issued a “buy” rating on the stock. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold”.

About MIRA Pharmaceuticals

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.